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Abstract
Alcohol and drugs of abuse consumption in young adults, including women of childbearing age, has experienced
significant increase over the past two decades. The use of questionnaires as the only measure to investigate prenatal alcohol
and drugs of abuse exposure underestimates the real prevalence of exposure and could mislead to wrong conclusions.
Therefore, the aim of this article was to compare reported rates of prenatal alcohol and drugs of abuse consumption with
biomarkers of exposure by a comprehensive review of the available literature. We searched MEDLINE and EMBASE databases
for articles catalogued between 1992 and 2015. We identified relevant published studies that assessed the comparison
between prenatal exposure to alcohol and drugs of abuse assessed by self-reported questionnaire of consumption versus
biomarkers of exposure. Thirteen studies were included regarding alcohol consumption, and seven of them about drugs of
abuse. Women who admitted consumption during pregnancy by questionnaire varied from 0 to 37% for alcohol, from 0 to
4.3% for cocaine, and 2.9% for tetrahydrocannabinol (THC). Positive biomarkers results ranged from 16 to 44% for alcohol, 15.
4% for cocaine, and from 4 to 12.4% for THC. Biomarkers should always complement questionnaires, as it has been shown
that self-report may underestimate prenatal exposure to substances of abuse.
Keywords: Prenatal exposure, Pregnancy, Questionnaire, Biomarkers, Biological matrices, Substances of abuse, Alcohol, Drugs
of abuse
Resumen
El consumo de alcohol y drogas de abuso en adultos jóvenes, incluyendo mujeres en edad fértil, ha experimentado
un aumento importante en las dos últimas décadas. El empleo de cuestionarios como única herramienta para detector la
exposición prenatal a alcohol y drogas de abuso supone una infraestimación de la prevalencia real de la misma y podría
llevar a conclusiones equivocadas. Por lo tanto, el objetivo de este estudio fue comparar las cifras declaradas de consumo
prenatal de alcohol y drogas de abuso con biomarcadores de exposición mediante una revisión de la literatura. Se buscaron
en MEDLINE y EMBASE artículos entre 1992 y 2015. Se identificaron los estudios publicados importantes que evaluaban la
comparación entre cuestionarios de consumo autoadministrados y biomarcadores de exposición. Se incluyeron 13 estudios
sobre el consumo de alcohol y 7 sobre drogas de abuso. Las mujeres que admitieron el consumo durante el embarazo por
cuestionario fueron entre el 0% y el 37% para el alcohol, entre el 0% y el 4,3% para la cocaína y el 2,9% para
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el tetrahidrocannabinol (THC). Los valores de los biomarcadores positivos fueron entre el 16% y el 44% para
el alcohol, el 15,4% para la cocaína y el 12,4% para el THC. Los biomarcadores deben acompañar siempre al cuestionario
ya que se ha demostrado que la autodeclaración puede infraestimar la exposición prenatal a sustancias de abuso.
Plain English summary
Alcohol and drugs of abuse consumption in young adults
has increased over the past two decades, also in pregnant
women. If we ask in a questionnaire for alcohol and drugs of
abuse during pregnancy, it will be difficult to know the real
consumption in most of cases. A biomarker is a substance
that can be detected in the body, i.e., in blood or in hair.
Therefore, the aim of this article was to compare reported
consumption of prenatal alcohol and drugs of abuse
consumption with biomarkers of exposure by a comprehen-
sive review of the available literature. We searched MED-
LINE and EMBASE databases for articles catalogued
between 1992 and 2015. We identified relevant published
studies that assessed the comparison between prenatal con-
sumption of alcohol and drugs of abuse assessed by ques-
tionnaire or by biomarkers. Thirteen studies were included
regarding alcohol consumption, and seven of them about
drugs of abuse. Women who admitted consumption during
pregnancy by questionnaire varied from 0 to 37% for alcohol,
from 0 to 4.3% for cocaine, and 2.9% for tetrahydrocanna-
binol (THC). Positive biomarkers results ranged from 16 to
44% for alcohol, 15.4% for cocaine, and from 4 to 12.4% for
THC. Biomarkers should always complement questionnaires,
as it has been shown that self-report may underestimate
prenatal consumption of substances of abuse.
Background
Alcohol and drugs of abuse consumption in young
adults and women of childbearing age has experienced
an increase over the past two decades. Since nearly 50%
of pregnancies are unplanned, prenatal exposure to alcohol
and/or drugs of abuse in the early stages of pregnancy is
relatively common. Drugs of abuse consumption rates in
Spain is one of the highest in Europe, especially for cocaine
and cannabis. According to the Spanish Drug Observatory
latest report [1], women aged between 15 and 34 years
admitted drugs of abuse consumption for the previous
12 months, 19.4, 4.3 and 1.8% for cannabis, cocaine and ec-
stasy, respectively.
Substances such as tobacco and alcohol show con-
sumption patterns with a considerable high prevalence
in women between 15 and 39 years old. The prevalence
of alcohol consumption for the last 12 months in
women from 15 to 34 years old and from 35 to 64 years
old is 80.1 and 77.7%, respectively [1]. In Sweden, it has
been reported that 30% of pregnant women continue the
consumption of alcohol while pregnant [2]. In USA, the
rate of current illicit drug use in the combined 2012–
2013 data was 14.6% among pregnant women aged 15 to
17, 8.6% percent among women aged 18 to 25, and 3.2%
among women aged 26 to 44. Among pregnant women
aged 15 to 44 in 2012–2013, an annual average of 9.4%
reported current alcohol use, 2.3% binge drinking, and
0.4% heavy drinking [3].
Prenatal exposure to these substances increases the risk
of obstetric complications and has serious consequences,
not only in the developing foetus, but also lifelong implica-
tions. The deleterious effects of ethanol during pregnancy
are well described by the all-encompassing term ‘Foetal
Alcohol Spectrum Disorder’ (FASD), which includes a wide
range of physical defects, behavioural, emotional and cogni-
tive deficits, as well as congenital anomalies [4]. Prenatal
cocaine use has been associated with placental abruption
and premature labour, as well as with increased rate of low
birth weight, microcephaly and congenital anomalies.
Gestational cannabis use is related to lack of attention,
impulsivity and deficits in learning and memory. Foetal
exposure to opiates has been related mainly to neonatal
withdrawal syndrome and poor obstetric outcome [5].
While brain damage caused by toxics consumption
cannot be repaired, we can achieve the best neurological
development of these children with the early onset of
follow up and, in this way, try to decrease the occur-
rence of secondary disabilities (poor school performance,
addictions, and mental health problems) and prevent re-
currence in subsequent pregnancies. Early detection of
prenatal exposure to toxic substances allows these
patients benefit from close monitoring of their develop-
ment, treatment, early recognition of withdrawal syn-
drome and implement timely interventions. For this
reason, identification of substance exposed infants is a
key factor on preventing alcohol and drugs of abuse re-
lated birth defects. This is a major public health problem
all over the world, with a severe impact on society.
There are few screening instruments to evaluate drug of
abuse consumption in pregnant women and most of them
have been designed to screen alcohol misuse. The most
widely used measures are the following validated ques-
tionnaires: T-ACE (Tolerance, Annoyance, Cut Down, Eye
Opener), TWEAK (Tolerance, Worried, Eye-openers,
Amnesia, K[C] Cut Down), AUDIT and its shorter ver-
sion, the C-AUDIT (Alcohol Use Disorders Identification
Test), MAST and its shorter version SMAST (Michigan
Alcoholism Screening Test) [6–8].
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There are also lots of “local questionnaires” which
include questions to screen for maternal alcohol con-
sumption during pregnancy that are currently used like
a standard tool by nursing staff [9, 10]. It is worthy of
note that these questionnaires do not reflect the risk of
alcohol use and show low to moderate specificity [6, 7].
Moreover, there are no specific validated questionnaires
about drugs of abuse during pregnancy.
Besides the lack of specificity and sensitivity of these
questionnaires, the problem of underreporting con-
sumption by pregnant women needs to be seriously con-
sidered. Subjects may underestimate their consumption
and/or are unwilling to disclose their habits during preg-
nancy due to fear of legal repercussions, guilt, memory
biases or lack of preparation on how to perform the
interview are some of the factors that can lead to
minimize or deny consumption [11, 12].
For all these reasons currently, a number of biomarkers
have been evaluated and are available for the purpose of
detecting prenatal exposure. Maternal hair and meconium
analysis are the most commonly matrices used to detect
prenatal exposure, since they allow to expand the detec-
tion window of the consumption. Maternal hair provides
information depending on its length (hair has a growth
rate if 1 cm per month) and meconium serves as a reser-
voir of foetal chemical exposures during the second and
third trimesters pregnancy [9, 13]. For the evaluation of
alcohol intake, detection of non-oxidative direct ethanol
metabolites such as fatty acid ethyl esters (FAEEs), ethyl
glucuronide (EtG) and ethyl sulphate (EtS) currently
appear most promising. Each of these biomarkers remain
positive in maternal serum and urine for a certain amount
of time after the cessation of alcohol intake (FAEEs in
serum up to 24 h and EtG in urine up to 5 days) and EtG
and FAEE can be detected in hair for months. Addition-
ally, it is known that once FAEEs are formed they do not
cross the human placenta; therefore if detected in meco-
nium they represent foetal exposure to ethanol [9, 14].
In some studies, other biomarkers have been used, like
carbohydrate-deficient transferring (CDT) and phospha-
tidylethanol (PEth) in mother blood, but they respond to
regular heavy or moderate alcohol consumption in the
previous 2–4 weeks [10, 15]. For the evaluation of drug
consumption, the presence of cocaine (COC), benzoyle-
cognine (BE), tetrahydrocannabinol (THC), amphet-
amine (AMP), metamphetamine (MDMA), opiates (OP)
can be determined in maternal hair and meconium using
standard chromatographic techniques. In some studies
maternal urine is also used but only detects exposure for
1–4 days prior to delivery [16].
Several authors recommend universal or directed
screening population of prenatal exposure to abuse sub-
stances using biomarkers. In some Mediterranean coun-
tries, although 99% of women declare absolute abstention
from drinking during pregnancy, FAEEs above 2 nmol/g
meconium (the cut-off internationally used to differentiate
heavy maternal alcohol consumption during pregnancy
from occasional or no use) ranged from 1.7% of samples
in Reggio Emilia, Italy to 44.5% in Barcelona, Spain [16,
17]. In the same cohorts, meconium analysis showed that
prevalence of opiates, cocaine and combined drug expos-
ure was 8.7, 4.4 and 2.2%, whereas structured interviews
only disclosed 1.3, 1.8 and 1.3% of mothers exposed to
opiates, cocaine and both drugs. Clearly, in these cohorts,
the usefulness of a questionnaire is absolutely futile [17].
We hypothesize that the use of questionnaires as the
only measure to investigate prenatal alcohol and drugs
exposure underestimate the real prevalence of exposure
and could mislead to wrong conclusions. Therefore, the
aim of this article was to compare reported rates of pre-
natal alcohol and drugs of abuse exposure with bio-
markers of exposure by a comprehensive review of the
available literature.
Methods
We searched in MEDLINE and EMBASE databases for
articles catalogued from 1992 to 2015 and published in
English language. We identified relevant published stud-
ies that considered the comparison between prenatal ex-
posure to alcohol and drugs of abuse assessed by
validated self-reported questionnaire versus biomarkers
of exposure (meconium, hair, urine, and serum). Some
biological matrices including umbilical cord blood and
sweat were not included since it only show very recent
consumption before the collection of the sample. Metab-
olites of substances of abuse in it could be subrogate
biomarkers of chronic consumption, but this point was
not included in our analysis. We included only con-
firmative assays with sophisticated analytical assays, not
drug screening assays, i.e. in urine. A positive assay in
urine needs a confirmative assay with gas/liquid
chromatography-mass spectrometry (GC-MS or LC-MS)
because of the risk of false positive results. A narrative
review was carried out searching combinations of key
words “pregnancy” AND “substances of abuse” OR “pre-
natal exposure” AND “questionnaire” OR “biomarkers”
OR “biological matrices” The major inclusion criteria
was “diagnosis/identification/detection of prenatal ex-
posure to drugs of abuse or alcohol”. The exclusion cri-
teria were not to meet all inclusion criteria. Data were
extracted by the authors in cooperation with bibliog-
raphy managers from the university and the hospital
library.
Results
The search strategy generated 13 references regarding
alcohol consumption for the final analysis (Fig. 1). The
main objectives in 8 of these studies were to compare
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self-reported ethanol intake with the detection of bio-
markers. In the other five, the objective was to estimate
the prevalence of alcohol consumption using biomarkers
and questionnaires although, as endpoints, they also
compared both screening methods. The number of
patients included varied widely between 51 and 1700
[18, 19]. The matrices used were meconium, hair [14,
18], urine [14] and serum [10, 15]. The main biomarkers
used were EtG and FAEE. On the other hand, the ques-
tionnaires used varied importantly between studies
(CAGE, AUDIT, CUAL, Parkyn Screening tool and PAU
or prenatal alcohol use interview) (Table 1).
The percentage of women who admitted consumption
in questionnaires varied from 0% [20, 21] to 37% [22]. In
the first group, positive results in biomarkers were up to
16% in both of them, whilst Hudson found up to 44%
positives for FAEE. The highest positive prevalence
through biomarkers was in the Spanish group led by
Pichini who found up to 95% positive for EtG [23].
The main results of 11 of these studies showed how
self-reported alcohol consumption is underestimated
(Fig. 1). Only one of them showed how maternal inter-
view for alcohol exposure is more sensitive than hair
analysis [18]. Regarding biomarkers, Derauf et al. and
Hutson et al. found no agreement between reported
ethanol intake during third trimester and FAEE, with ab-
sence of FAEE in infants meconium whose mothers ad-
mitted drinking [22, 24]. Pichini et al. could not find a
good correlation between FAEE, EtG and EtS [23, 25]
(Table 2).
Seven articles were included for the final analysis of
drugs of abuse during pregnancy studies. (Figure 1) The
main objective was to determine the incidence or preva-
lence of prenatal drug exposure in 4 of them. The other
3 studies aimed to compare biomarkers and question-
naires. The number of patients included in these studies
varied from 107 to 1800 [22, 26]. The matrixes used
were hair (2 studies), meconium (3 studies) or both (2
Fig. 1 The flow diagram shows the screening process of retrieved articles, including the number and reason of exclusion
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studies). These studies agreed that either meconium or
hair analysis showed to be more sensitive than maternal
interview for drugs of abuse. Garcia-Serra et al. found
more sensitivity in hair analysis than maternal meco-
nium to detect cannabis [16] (Table 3).
The percentage of women who admitted drugs of
abuse consumption in questionnaires varied from 0 to
4.3% for cocaine and 2.9% for THC [11, 18]. Positive re-
sults in biomarkers were up to 4% for THC, whilst Len-
dorio et al. found up to 15.4% positive for cocaine and
12.4% positives for THC [18].
The collected data showed that the use of biomarkers
was more sensitive than maternal interview to detect
drugs of abuse consumption in pregnant women as re-
ported with alcohol consumption (Table 4).
Discussion
Recent evidences support that the use of questionnaires
as the only measure to investigate prenatal alcohol and
drugs of abuse exposure underestimate the real preva-
lence. From the 15 studies comparing questionnaire ver-
sus biomarkers (8 in alcohol and 7 in other drugs of
abuse) which questionnaires were compared with bio-
markers, 13 of them showed an underestimated expos-
ure by the questionnaire. This fact has been recently
supported by a systematic review and meta-analysis
showing that prenatal alcohol exposure as measured by
meconium testing was 4.26 (95% CI: 1.34–13.57) times
the pooled prevalence as measured by maternal self-
reports [27]. Reasons why women don’t disclose sub-
stances of abuse consumption during pregnancy are
related to shame, guilty or legal problems, especially in
the US where results of drug assays have been used to
terminate custody or prosecute women.
At the moment, questionnaires are widely used as they
are a simple and cheap tool. However, there are no uni-
versal validated questionnaires and it has been repeat-
edly proved that they are not reliable and they
underestimate prevalence of exposure to drugs of abuse
and alcohol. Both maternal hair and meconium have
been used as biological matrices in which to detect drugs
of abuse consumption in pregnancy and have shown
higher prevalence than clinical interviews and traditional
screening methods such as blood tests and/or urine. The
main advantage of these two biological matrices is that
they extend the detection window considerably, as each
centimetre of hair from maternal scalp corresponds to
one-month period retrospectively and meconium con-
tains the substances that the foetus has been exposed in
uterus during the last two trimesters of the pregnancy.
Biomarkers have been shown to be a valuable tool that
could solve the problem of underreporting. On the
downside, there are still a few pending questions about
biomarkers to ascertain, as they can’t evaluate
consumption during the first trimester nor detect very
low alcohol consumptions. Some biomarkers of prenatal
exposure to ethanol such as CDT and APAs can produce
false positives due to its concentration increases in the
third trimester of pregnancy and shows also high values in
people with diabetes [28]. For instance, urine tests show
limitations related to detection window and are not useful
for alcohol detection. Hair tests are limited by type of hair
and amounts collected, use of hair products and hair pro-
cessing protocols [7]. When initial screening drug tests
generate positive results, gas/liquid chromatography-mass
spectrometry analysis (GC-MS or LC-MS) must be done
in samples to confirm the presence of drugs in order to
eliminate the false positive possibility. Some drugs as anti-
biotics, analgesics or antihistamines have been reported as
sources of false positives so it is important to give a
complete and accurate history of all prescription, OTC,
and vitamin/dietary supplement/herbal drug use prior to
the time of the sample collection. Despite these weak-
nesses, it is important to note that there are very specific
and sensitive biomarkers, as PEth, the only one that
detects alcohol in all patients without generating false
negative and whose blood concentration correlates with
the amount of ingested ethanol. The liquid chromatog-
raphy coupled to tandem mass spectrometry (LC-MS-
MS) is considered the most common technique to detect
it in blood and urine, whereas the GC-MS is the is also
frequently used in hair due to the solid nature of the
matrix [29]. However, although the analytical method-
ology is fully developed, screening with biomarkers would
be difficult to implement as it is more expensive and
requires resources not available in every small clinic. The
only biological screening test that is feasible for use during
the pregnancy (antepartum) is urine toxicology screening.
This test has many limitations. Urine screening tests can
be used, but they must be confirmed by GC-MS or LC-
MS tests. Recently it has been published the recommenda-
tion of using these tests in clinical settings and in our
hospital we use it from a long time, not only with research
purposes.
Of note, a relevant problem is the refusal of some
women to accept the biomarker analysis because the
results could be used to determine custody of children in
case of divorce or to prosecute some of these women in
countries such as USA. For these reasons, an informed
consent must be required. Only in emergency cases when
clinic staff determine a severe danger for the foetus, the
principle of the best interest of the child will be applied.
Therefore, it can be hypothesized that biomarkers could
be used as a validated confirmation when clinicians
suspect of alcohol or other drugs of abuse consumption
or in the context of epidemiological and clinical studies.
When clinicians find a positive for alcohol and/or drugs
of abuse in biomarkers analysis not mentioned in
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questionnaires, different protocols promoted by public
heath institutions have to be activated, focusing on the
protection of the child and care, advice and help of these
pregnant women to stop the use of alcohol and/or drugs.
In this review, the prevalence of consumption during
pregnancy has shown to be significantly high. The
highest prevalence of alcohol consumption was found
the be up to 95% in the Spanish group led by Pichini
and Lendorio et al. that found a prevalence of up to
15.4% positive for cocaine and 12.4% positive for THC
through biomarkers [18, 30]. Prenatal exposure to
alcohol and drugs of abuse increases risk not only for
obstetric complications but also of lifelong consequences
for the newborn. Biomarkers have shown to be the key
to detect this consumption [31, 32].
The brain damage caused by the prenatal toxic expos-
ition cannot be repaired. So, the early detection of
prenatal exposure to alcohol and drugs of abuse allow
these patients to benefit from early stimulation and close
monitoring of their development, which will allow the
implementation of timely and early interventions and
therapies that are the clue to try to decrease the occur-
rence of secondary disabilities [5, 33].
Conclusions
Prevalence of alcohol and drugs of abuse consumption
during pregnancy is significantly high, so it is also prenatal
exposure to these substances. Early detection of this
exposure is essential to carry out therapeutic interventions
(as in neonatal abstinence) but also to prevent deleterious
effects of this exposure through early years of life.
This study has implications affecting public health
programs and policies. At the moment, screening is car-
ried out mostly through questionnaires for alcohol and
drugs of abuse, but these have proved to be unreliable
when compared to biomarkers. Undetected consumption
could have deleterious effects over children’s health.
Therefore, questionnaires underdiagnose prenatal expos-
ure to alcohol and drugs of abuse and could promote a
lack of care of the newborn. We propose the use bio-
markers as the main screening tool in patients in environ-
ments with high prevalence of alcohol and drugs of abuse
consumption, along with questionnaires. At the present
time studies with biomarkers (maternal hair or neonatal
meconium) may not be available in all services, but they
should also be considered in those cases with suspected
consumption although patients deny it in questionnaires.
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